Impact BioMedical, Inc. (IBO)vsModerna Inc (MRNA)
IBO
Impact BioMedical, Inc.
$0.46
+4.35%
HEALTHCARE · Cap: $52.83M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 6365614% more annual revenue ($2.23B vs $35,000). IBO leads profitability with a 2260.0% profit margin vs -141.4%. IBO earns a higher WallStSmart Score of 32/100 (F).
IBO
Avoid32
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IBO.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Keeps 2260 of every $100 in revenue as profit
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -112.2% — below average capital efficiency
Revenue declined 57.1%
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : IBO
The strongest argument for IBO centers on P/E Ratio, Profit Margin. Profitability is solid with margins at 2260.0% and operating margin at -23400.0%.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : IBO
The primary concerns for IBO are EPS Growth, Market Cap, Return on Equity.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
IBO profiles as a declining stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
IBO generates stronger free cash flow (470,000), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
IBO scores higher overall (32/100 vs 21/100), backed by strong 2260.0% margins. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Impact BioMedical, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Impact BioMedical, Inc. is an innovative biotechnology company focused on developing groundbreaking therapeutics and technologies to address critical healthcare challenges. Utilizing advanced research methodologies, the firm aims to improve patient outcomes and overall quality of life. With a robust intellectual property portfolio and an emphasis on scientific rigor, Impact BioMedical is well-positioned for growth in the evolving healthcare market. Its extensive product pipeline and strategic collaborations offer attractive investment opportunities for institutional investors interested in the accelerating biopharmaceutical sector.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?